Pharma Stock Roundup: Mylan, Teva Q1 Earnings, Roche Drug Misses In Pivotal Study
Zacks Investment Research | May 12, 2017 08:49AM ET
This week, companies like Mylan (NASDAQ:MYL) , Allergan (NYSE:AGN) and Teva (NYSE:TEVA) reported earnings results. The spotlight also remained on Roche (OTC:RHHBY) which saw its immuno-oncology drug fail in a pivotal study.
Recap of the Week’s Most Important Stories
A Look at Earnings Results: Mylan, Allergan and Teva all reported first quarter results this week. While Mylan topped earnings estimates, it missed on sales with EpiPen being impacted by increased competition and the presence of a lower priced authorized generic. (Read more: Merck, Pfizer Report Q1 Earnings, J&J Talc Powder Lawsuit ).
What's Next in the Pharma World?
Watch out for an update from Johnson & Johnson (NYSE:JNJ) regarding its Pharmaceutical businesses next week.
Sell These Stocks. Now.
Just released, today's 220 Zacks Rank #5 Strong Sells demand urgent attention. If any are lurking in your portfolio or Watch List, they should be removed immediately. These sinister companies because many appear to be sound investments. However, from 1988 through 2016, stocks from our Strong Sell list have actually performed 6X worse than the S&P 500.
Zacks Investment Research
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.